Information Provided By:
Fly News Breaks for July 16, 2018
VRTX
Jul 16, 2018 | 08:59 EDT
Jefferies analyst Michael Yee raised his price target for Vertex Pharmaceuticals to $210 saying he wants to own the stock as a "top large cap idea." The analyst expects good Q2 results on July 25 and ramp of new cystic fibrosis drug Symdeko. He believes 2019 consensus estimates are too low given that the triple pill could start in 2019. Yee keeps a Buy rating on Vertex.
News For VRTX From the Last 2 Days
There are no results for your query VRTX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.